Literature DB >> 26622444

Retrospective analysis of the clinicopathological characteristics of gastrointestinal neuroendocrine neoplasms.

Zhiqiang Wang1, Wenliang Li1, Tianxing Chen2, Jun Yang1, Lilin Luo2, Lianyu Zhang3, Baocun Sun3, Rui Liang2.   

Abstract

The aim of the present study was to analyze and summarize the clinicopathological characteristics and factors affecting prognosis for patients with gastrointestinal neuroendocrine neoplasms (GINENs). Retrospective analysis was conducted on the clinicopathological data of 74 patients who were diagnosed with GINEN, and immunohistochemical methods were used to detect the expression levels of relevant markers [synaptophysin (Syn), chromogranin A (CgA) and Ki-67]. Among the 74 cases with GINEN, there were 39 males and 35 females, with an average age of 56.9 years. There were 32 neoplasms in the rectum, 29 in the stomach, 6 in the colon, 2 in the small intestine and 5 in the appendix. All 74 cases underwent surgical resection. According to the World Health Organization Classification of Tumors of the Digestive System (2010), the diagnosis of the 74 cases showed 41 cases (55.4%) of neuroendocrine tumor (NET; 25 cases of G1 and 16 cases of G2), 21 cases (28.4%) of neuroendocrine carcinoma (NEC) and 12 cases (16.2%) of mixed adenoneuroendocrine carcinoma (MANEC). Additionally, 19 cases had metastasis to lymph nodes. During 10-34 months of follow-up, 15 patients had distant metastasis and 24 patients succumbed, and the accumulative survival rate in 1 or 2 years was 87.8 and 74.3%, respectively. Six factors, namely neoplasm size, depth of invasion, lymph node metastasis, distant metastasis, pathological type and the expression or lack of expression of CgA, significantly affected the survival time of patients. Definitive diagnosis of GINEN mainly relies on pathological diagnosis. GINENs with different histopathological types and grading have different clinicopathological characteristics and prognosis: NETs are mainly early lesions with a good prognosis, whereas NECs and MANECs have high malignancy and strong invasion with a worse prognosis.

Entities:  

Keywords:  gastrointestinal tract; neuroendocrine neoplasm; pathology; retrospective analysis

Year:  2015        PMID: 26622444      PMCID: PMC4533220          DOI: 10.3892/etm.2015.2634

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  29 in total

1.  Gastroenteropancreatic neuroendocrine tumors: incidence and treatment outcome in a single institution in Korea.

Authors:  Taekyu Lim; Jeeyun Lee; Jae J Kim; Jong Kyun Lee; Kyu Taek Lee; Young Ho Kim; Kwang-Won Kim; Sung Kim; Tae Sung Sohn; Dong Wook Choi; Seong Ho Choi; Ho-Kyung Chun; Woo Young Lee; Kyoung-Mee Kim; Kee-Taek Jang; Young Suk Park
Journal:  Asia Pac J Clin Oncol       Date:  2011-09       Impact factor: 2.601

2.  Management of early gastrointestinal neuroendocrine neoplasms.

Authors:  Hans Scherübl; Robert T Jensen; Guillaume Cadiot; Ulrich Stölzel; Günter Klöppel
Journal:  World J Gastrointest Endosc       Date:  2011-07-16

3.  Plasma chromogranin A levels predict survival and tumor response in patients with advanced gastroenteropancreatic neuroendocrine tumors.

Authors:  Wen-Chi Chou; Jen-Shi Chen; Yu-Shin Hung; Jun-Te Hsu; Tse-Ching Chen; Chien-Feng Sun; Chang-Hsien Lu; Tsann-Long Hwang
Journal:  Anticancer Res       Date:  2014-10       Impact factor: 2.480

4.  Prognostic clinicopathologic factors in longitudinally followed patients with metastatic small bowel carcinoid tumors.

Authors:  Thomas Curran; Sheryl Tulin-Silver; Kalpesh Patel; Stephen Ward; Melissa Schneiderman; Noam Harpaz; Myron Schwartz; Steven Itzkowitz; Richard R P Warner; Michelle Kang Kim
Journal:  Pancreas       Date:  2011-11       Impact factor: 3.327

Review 5.  Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE).

Authors:  R Garcia-Carbonero; J Capdevila; G Crespo-Herrero; J A Díaz-Pérez; M P Martínez Del Prado; V Alonso Orduña; I Sevilla-García; C Villabona-Artero; A Beguiristain-Gómez; M Llanos-Muñoz; M Marazuela; C Alvarez-Escola; D Castellano; E Vilar; P Jiménez-Fonseca; A Teulé; J Sastre-Valera; M Benavent-Viñuelas; A Monleon; R Salazar
Journal:  Ann Oncol       Date:  2010-02-05       Impact factor: 32.976

Review 6.  Surgery for GEP-NETs.

Authors:  Ulrich Knigge; Carsten Palnæs Hansen
Journal:  Best Pract Res Clin Gastroenterol       Date:  2012-12       Impact factor: 3.043

Review 7.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

8.  Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study.

Authors:  Daniel Castellano; Emilio Bajetta; Ashok Panneerselvam; Stephen Saletan; Walter Kocha; Thomas O'Dorisio; Lowell B Anthony; Timothy Hobday
Journal:  Oncologist       Date:  2012-12-21

9.  Clinical and prognostic features of rectal neuroendocrine tumors.

Authors:  Brett Weinstock; Stephen C Ward; Noam Harpaz; Richard R P Warner; Steven Itzkowitz; Michelle Kang Kim
Journal:  Neuroendocrinology       Date:  2013-11-05       Impact factor: 4.914

Review 10.  Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors.

Authors:  Diane L Reidy; Laura H Tang; Leonard B Saltz
Journal:  Nat Clin Pract Oncol       Date:  2009-02-03
View more
  12 in total

1.  Sex comb on midleg like-2 is a novel specific marker for the diagnosis of gastroenteropancreatic neuroendocrine tumors.

Authors:  Jiao-Jiao Yang; Hua Huang; Ming-Bing Xiao; Feng Jiang; Wen-Kai Ni; Yi-Fei Ji; Cui-Hua Lu; Run-Zhou Ni
Journal:  Exp Ther Med       Date:  2017-06-26       Impact factor: 2.447

2.  The correlation and clinical implication of VEGF-C expression in microvascular density and lymph node metastasis of gastric carcinoma.

Authors:  Yong Dai; Jinbo Jiang; Yanlei Wang; Zutao Jin; Sanyuan Hu
Journal:  Am J Transl Res       Date:  2016-12-15       Impact factor: 4.060

3.  A Case Report: Gastric Mixed Neuroendocrine-Nonneuroendocrine Neoplasm with Aggressive Neuroendocrine Component.

Authors:  Quang Duy Pham; Ichiro Mori; Robert Y Osamura
Journal:  Case Rep Pathol       Date:  2017-05-24

Review 4.  Systematic review of resecting primary tumor in MNETs patients with unresectable liver metastases.

Authors:  Jingfei Guo; Qian Zhang; Xinyu Bi; Jianguo Zhou; Zhiyu Li; Zhen Huang; Yefan Zhang; Muxing Li; Xiao Chen; Xuhui Hu; Chi Yihebali; Junbo Liang; Jianmei Liu; Jianjun Zhao; Jianqiang Cai; Hong Zhao
Journal:  Oncotarget       Date:  2017-03-07

5.  Two patients with rare mixed adenoneuroendocrine carcinomas of the rectum.

Authors:  Safak Gül-Klein; Marianne Sinn; Philipp Sebastian Jurmeister; Matthias Biebl; Sascha Weiß; Beate Rau; Hendrik Bläker; Johann Pratschke; Felix Aigner
Journal:  SAGE Open Med Case Rep       Date:  2018-03-14

6.  Gastrointestinal mixed adenoneuroendocrine carcinoma: a population level analysis of epidemiological trends.

Authors:  Jiakun Wang; Aoxiao He; Qian Feng; Ping Hou; Junjun Wu; Zhihao Huang; Zhouqing Xiao; Chi Sun; Wenjun Liao; Linquan Wu
Journal:  J Transl Med       Date:  2020-03-14       Impact factor: 5.531

7.  Clinicopathological characteristics and prognosis of 77 cases with type 3 gastric neuroendocrine tumours.

Authors:  Yuan-Liang Li; Xu-Dong Qiu; Jie Chen; Yu Zhang; Jie Li; Jian-Ming Xu; Chao Wang; Zhi-Rong Qi; Jie Luo; Huang-Ying Tan
Journal:  World J Gastrointest Oncol       Date:  2020-12-15

8.  Utility of CT in differentiating liver metastases of well-differentiated gastroenteropancreatic neuroendocrine neoplasms from poorly-differentiated neuroendocrine neoplasms.

Authors:  Yong Cui; Xiaoting Li; Shunyu Gao; Zhongwu Li; Yanling Li; Ming Lu; Yingshi Sun
Journal:  Chin J Cancer Res       Date:  2018-02       Impact factor: 5.087

9.  CEA Level, Radical Surgery, CD56 and CgA Expression Are Prognostic Factors for Patients With Locoregional Gastrin-Independent GNET.

Authors:  Yuan Li; Xinyu Bi; Jianjun Zhao; Zhen Huang; Jianguo Zhou; Zhiyu Li; Yefan Zhang; Muxing Li; Xiao Chen; Xuhui Hu; Yihebali Chi; Dongbing Zhao; Hong Zhao; Jianqiang Cai
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

10.  A Previously Undescribed Presentation of Mixed Adenoneuroendocrine Carcinoma.

Authors:  Javier De Luca-Johnson; Maryam Zenali
Journal:  Case Rep Pathol       Date:  2016-11-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.